DOI: 10.1055/s-00000097

Deutsche Zeitschrift für Onkologie

LinksClose Window

References

Escudier B, Koralewski P, Pluzanska A, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Moore N. investigators. obotA.
A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-a2a vs placebo/interferon- a2a as first-line therapy in metastatic renal cell carcinoma. 
J Clin Oncol 2007; 25

Download Bibliographical Data

Search in:

We do not assume any responsibility for the contents of the web pages of other providers.